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ABSTRACT 
Conduct systematic analysis of the state of the supply of Ukraine with 
medications with chondroprotective activity. The Unified Clinical Protocol 
of Primary, Secondary (specialized) Medical Care allows doctors to control 
the state of a patient at every stage of illness and guarantees the effective 
treatment and prophylaxis of the locomotor system (LMS) pathologies. 
As a result of the chondroprotective medication range analysis it was 
determined that the pharmaceutical market of Ukraine is represented by 40 
trade names of medications. The top market share of chondroprotective 
medications in Ukrainian market belongs to the foreign producers (52.5%), 
while domestic medications occupy 47.5%. In general the nomenclature of 
Ukrainian medications is provided by 6 manufacturing companies. Three 
pharmaceutical companies are the leaders producing 5 names of medications 
each (12.5% each): Pharmaceutical company “Zdorovye” (Kharkiv), PrJSC 
“Fitofarm” (Bakhmut, formerly Artemivsk, Donetsk region), JSC “Farmak” 
(Kyiv). Out of 40 trade names the medications are mainly produced: as 
coated tablets – 12 medications (30%), as solutions for injections – 11 items 
(27.5%), as capsules – 7 (17.5%), as soft dosage forms – 6 medicines (15%), 
and powders for oral administration – 4 items (10%) [1]. 
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Introduction. The locomotor system (LMS) disorders are one of the reasons for the incapacity 
to work and physical disability of population, causing the impairment of quality of life and bringing 
about considerable treatment expenses. The LMS pathologies affect people of all age categories all 
over the world. In 2017 they were the leading reason for disabilities in four out of six regions of the 
World Health Organization (WHO) (ranking second in the Eastern Mediterranean Region and third in 
the African Region). Though the LMS disorders incidence increases with age, younger people also 
tend to suffer from them, often at the age of the most economic activity. 
Joint diseases comprise one of the most widely spread LMS pathologies. Inflammatory 
disorders are dangerous by the fact that they can transform into an irreversible process and might lead 
to disabilities, to the full or partial incapacity to work, as well as promote the development of 
comorbid conditions. According to the International Statistical Classification of Diseases and Related 
PHARMACY 
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Health Problems of the 10th revision, among all the LMS disorders osteoarthrosis (OA, M15-M19 by 
ICD-10) is one of the most widely spread degenerative-dystrophic disorders, which comprises the 
most complicated socio-economic and medical problem. According to the WHO about 4% of the 
population of the Earth suffers from OA, which in 10% of cases is the actual cause of disabilities. The 
attack rate of adult population of working age since 2008 has been increasing by an average of 4.3% 
yearly – from 80.8 to 91.2%; in the population over working age the growth by 1.9% has been 
indicated – from 157.6 to 166.8% [2, 3]. 
According to the ICD-10 the terms “osteoarthrosis”, “arthrosis”, “osteoarthritis” are synonyms and 
only differ by the local classifications depending on the country where applied. The term “osteoarthrosis” is 
mainly used in Ukraine, while “osteoarthritis” is more common for Europe and the USA. OA ranks first 
among the disorders of rheumatic profile (60-80%) and has a tendency of incidence growth among the 
youth. According to the WHO, OA of knee joints is among five main reasons of the incapacity to work in 
women, and among ten – in men. OA is one of the main reasons of early incapacitation and disabilities, 
being second in this regard only to the ischemic heart disease (IHD) [4, 5]. 
In the USA 39 million of arthritis patients see a doctor yearly, with over 500 thousand of them 
being hospitalized. Further, the costs associated with medical care comprise 15 billion dollars, while 
the total economic losses – 65 billion dollars. Prognostic statistical data show that by 2020 the 
incidence of arthritis might comprise about 60 million people, i.e. almost 20% of the population, 11 
million of which might become disabled, unless the situation is intervened into [6, 7]. 
According to the official statistics of diseases registered in the health care organizations within 
the last several years, the statistical insights and social importance of musculoskeletal system (MSS) 
and connective tissue disorders in Ukraine looks as follows.  
As for official statistics, 26.614,512 cases were registered in 2017 for the first time, 4.65% of 
which comprised the MSS and connective tissue disorders, i.e. 2878 cases per 100,000 population.  
OA is the most widely spread MSS disorder in Ukraine. According to the official statistical 
data the OA incidence in Ukraine comprises 2200,6 cases per 100,000 population. The OA incidence 
in population (6.43%) increases with age and reaches maximum values (13.9%) in individuals over 45 
years of age. The occurrence among men and women of working and retirement age also varies. In 
men it is 32% less (423.1), than in women (558.8). In people of working age it is 2.7 times less (338.9) 
than in retired individuals (931.1) [8, 9]. 
According to the National Institute for Strategic Studies of the Ministry of Health of Ukraine 
the share of bone fractures among all traumatic injuries comprised 86.4% in 2016, which was equal to 
3,500 patients per 100,000 population. The number of patients that were losing the working capacity 
reached 1,58 million people (or 3.6% of all the population of Ukraine). The greater part of fractures 
was provoked by MSS disorders. The carried out analysis of fractures in adults between 18 and 75 
years of age (among which the most numerous group (40%) comprised the patients between 40 and 59 
years) showed that in the vast majority of cases (51.31%) the injuries were home accidents, the second 
in frequency were injuries sustained in the street (29.98%), while 10.18% patients sustained injuries as 
a result of road accidents. The most common fracture localizations were in various segments of upper 
and lower extremities (41.1 and 54.0 % respectively), while concomitant injuries were registered in 
15.9% of cases. The most frequent fractures of upper extremities were humerus fractures (23.1%); in 
addition, concerning the fractures of specified localizations, the highest frequency was characteristic 
of patients older than 60, which might be due to the decrease of strength characteristics of bone tissue 
in patients of the indicated age group [10, 11]. 
According to the research carried out by the National Institute for Health and Care Excellence 
(NICE), 2,5 million of women and 900,000 of men among the population in Ukraine are affected by 
osteoporosis (OP). 50% of the patients become disabled as a result of the disease, and 20% – die. 
Fractures comprise one of the most serious OP complications. The bone mass loss depends on the 
gender: in women – with the speed of 0.75-2.4% per year, and in men – 0.4-1.2%. In addition, the 
process starts in women at the age of 35 years, while in men – after 50 years. The OP incidence among 
women after menopausal period comprises 14% at the age of 50-59 years, 22% – at 60-69 years of 
age, 39% – between 70 and 79 years of age, and 70% – at the age of 80 and over. Thus, about 80% of 
OP patients are women, and in people over 50 years of age, in one case of two women and in one of 
eight men, there is a high probability of fracture occurrence [12].  
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Given the expected increase in life expectancy within the next coming years the increase in the 
number of osteoporotic fracture incidence will be observed. Thus, by 2035 the number of proximal 
femoral fractures is expected to grow by 36% in men and by 43% in women [13]. 
Purpose of the research is to determine the level of the supply of the population of Ukraine 
with chondroprotective medicines based on the data from marketing and pharmacoeconomic analysis. 
Material and methods. The current research was carried out using the system approach. The 
MSS incidence was analyzed based on the official statistical data. The data from the State Register of 
Medications, information resources and official websites of pharmaceutical companies were used for 
the marketing analysis. The marketing data on market prices for medications were used for the price 
indices analysis. The indices of price variations, liquidity and solvency adequacy were calculated to 
assess the accessibility of chondroprotective medications. 
Research results. The complex therapy of locomotor system disorders never goes without 
medications with chondroprotective activity. Today the range of medications with chondroprotective 
activity of domestic and foreign production is fairly broadly represented in the pharmaceutical market 
of Ukraine [14, 15]. 
Medications used for the LMS disorders treatment must comply with the guidelines of the 
Unified Clinical Protocol, which is created in accordance with the Methods for the development and 
implementation of medical standards (unified clinical protocols) of medical aid on the evidence-based 
medicine principles, approved by the Order of the Ministry of Health of Ukraine of 28.09.2012 № 751 
“On the creation and implementation of medical and technological documents on the medical aid 
standardization in the system of the Ministry of Health of Ukraine”. Such organizations as NICE and 
SIGN (Scottish Intercollegiate Guidelines Network), as well as the National Osteoporosis Guideline 
Group (NOGG), being based on the evidence-based medicine principles, have determined the optimal 
ways of the LMS pharmacotherapy management [16]. 
Depending on the rate of response the medications used in the LMS disorders treatment are 
classified into the fast-acting and slow-acting ones. SYSADOA (Symptomatic Slow Acting Drugs for 
OsteoArthritis), such as glucosamine, chondroitin sulfate, diacerein, hyaluronic acid, show 
symptomatic effect and low toxicity (Table 1) [17, 18]. 
Table 1. Medications used in the LMS disorders treatment  
Medications that modify the symptoms 
Fast Acting Slow Acting 
• Analgetics; 
• Non-steroidal anti-inflammatory drugs (NSAIDs): 
paracetamol (acetaminophen), ibuprofen, diclofenac, 
celecoxib, rofecoxib, tiaprofenic acid, meloxicam, 
nimesulide; 
• Narcotic agents (tramadol) 
• Glucocorticosteroids: triamcinolone, 
betametasone 
• Chondroitin sulfate; 
• Glucosamine; 
• Glucosamine + Chondroitin sulfate; 
• Soy/avocado compounds; 
• Diacerein; 
• Hyaluronic acid; 
• Glucosaminoglycan-peptide complex; 
• Extract of marine organisms 
Development of slow acting anti-inflammatory and structurally modifying agents – 
chondroprotectors – is the doubtless achievement of modern pharmacotherapy [19, 20]. 
The prescription of combined medications is preferred in clinical practice, which, on the one 
hand, allows achieving the additive effect in treatment, and increasing the treatment compliance, on 
the other hand. On prescription of combination medications the glucosaminoglycan synthesis by 
chondrocytes in increased by 96.6% compared to 32% in case of monotherapy. Application of 
combination medications treatment (glucosamine + chondroitin) objectively increases the number and 
sizes of chondrocytes per unit area of joint cartilage [21, 22]. 
We have carried out analysis of average retail prices of chondroprotective medications, which 
are registered in Ukraine and are represented in pharmacy institutions. The research on the pricing 
policy of chondroprotective medications in Kharkiv pharmacies was conducted during the period of 
01.06 to 01.07 2019.  
The range of medications with chondroprotective activity in pharmacy chains of Kharkiv city 
are represented by 40 trade names (Tables 2, 3). 
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Table 2. Analysis of retail prices of monotherapy medications with chondroprotective activity 
in pharmacies of Kharkiv city (2019)  
№ Trade name / 
Manufacturer 
Dosage form, 
strength, amount  
per unit 
Pmin, 
UAH 
Pmax, UAH Δ, UAH Cliq Сa.s. 
1 2 3 4 5 6 7 8 
MONOTHERAPY MEDICATIONS 
M01A X Other anti-inflammatory and antirheumatic agents, non-steroids 
M01A X05 Glucosamine 
1 Artiflex, “Zdorovye”, 
Ukraine 
powder for oral 
solution, 1.5 g per 
4.0 g packet, №20 
429 598 169 0,39 4,76 
2 Glucosamin Orion 
Corp., Finland 
powder for oral 
solution, 
1500 mg per 
pack, №20 
- - - - - 
3 Glucosate, 
“Biopharma”, Ukraine 
solution for 
injections, 
502,5 mg per 1 ml 
ampule, №5 
287 368 81 0,28 3,04 
4 Dona, “MEDA Pharm 
GmbH & Со”, 
Germany 
powder for 
oral solution, 
1500 mg per 
sachet, №20 
556 737 181 0,33 5,99 
5 Dona, “MEDA Pharm 
GmbH & Со”, 
Germany 
solution for 
injections, 
400 mg/ml, №6 
537 709 172 0,32 5,78 
6 Sinarta, “Farmak”, 
Ukraine 
powder for oral 
solution, 1,5 g 
per 3,95 g 
sachet, №30 
300 386 86 0,29 3,18 
7 Sinarta, “Farmak”, 
Ukraine 
solution for 
injections, 200 
mg/ml in 2 ml 
ampoule, №5 
391 558 167 0,43 4,40 
 М01А Х25 Chondroitin sulfate 
8 Artrida, Haupt Pharma 
Livron S.A.S, France 
solution for 
injections, 100 
mg/ml in 2 ml 
ampoule, №10 
398 527 129 0,32 4,29 
9 Artedja, “Fitofarm”, 
Ukraine 
solution for 
injections, 
200 mg in 2 ml 
ampoule, №10 
447 602 155 0,35 4,86 
10 Artedja, “Fitofarm”, 
Ukraine  
emulgel, tube 40 g 78,5 98,3 19,8 0,25 0,82 
11 Artiflex Chondro, 
“Zdorovye”, Ukraine 
solution for 
injections, 
100 mg/ml in 2 ml 
ampoule, №10 
441,70 615,6 173,9 0,39 4,90 
12 Artrox, “Novofarm-
Biosynthes”, Ukraine 
solution for 
injections, 
100 mg/ml in 
2 ml vial, №10 
388,4 496 137,6 0,28 4,10 
13 Mucosat NEO, 
“Belmedpreparaty”, 
Republic of Belarus 
solution for 
injections, 200 
mg/2 ml in 2 ml 
ampoule, №10 
580 791 
 
211 0,36 6,35 
14 Structum, Pierre 
Fabre Medicament 
Production, France 
capsules 795 931 136 0,17 8 
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Continuation of table 2. 
1 2 3 4 5 6 7 8 
15 Chondroitin Fitofarm, 
“Fitofarm”, Ukraine 
emulgel 5 % 
40 g 
54 111,4 57,4 1,06 0,77 
16 Chondrosat, 
“Biopharma”, Ukraine 
solution for 
injections, 
100 mg/ml in 2 ml 
ampoule, №10 
447 667 220 0,49 5,16 
17 Chondroflex, 
“Ternofarm”, Ukraine 
ointment, 50 mg, 
tube 30 g 
40,3 59 18,7 0,46 0,46 
18 Hondra-Syla, 
“Farmak”, Ukraine 
ointment 5% 
tube 30 g 
- - - - - 
Note: Pmin – minimal price; Pmax – maximal price; Δ – difference between the maximal and minimal 
prices; Сliq – liquidity coefficient; Ca.s. – solvency adequacy coefficient; UAH – Ukrainian hryvnia.  
Table 3. Analysis of retail prices of combination medications with chondroprotective activity 
in pharmacies of Kharkiv city (2019) 
№ Trade name / Manufacturer Dosage form, 
strength, amount 
per unit 
PPmin, 
UAH 
PPmax, 
UAH 
Δ Δ, 
UAH 
CCliq СCa.s. 
1 2 3 4 5 6 7 8 
M01A X20** Combinations 
Chondroitin sulfate + Glucosamine + Methylsulfonylmethane  
1 Arthron TriActive, Unipharm Inc., 
USA 
coated tablets, 
№60  
4456 6620 1164 00,36 44,98 
M01B ANTI-INFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION  
M01B X Other anti-inflammatory/antirheumatic agents in combination with other drugs 
Chondroitin sulfate + Glucosamine + Potassium diclofenac 
2 Movex Active, “Movi Health GmbH”, 
Switzerland 
coated tablets, 
400 mg +500 mg 
+50 mg, №60 
3370 4438 668 00,18 33,74 
3 Protechon Fast, Organosyn Life 
Sciences, India 
coated tablets, 
400 mg 
+500 mg, №60 
2278 3335 557 00,20 22,84 
Chondroitin sulfate + Glucosamine + Ibuprofen 
4 Theraflex Advance, “Bayer”, Germany capsules, 
200 mg +250 mg 
+100 mg, №60 
2231 3343 1112 00,48 22,6 
5 Artiflex Ultra, “Zdorovye”, Ukraine capsules, 
200 mg +250 mg 
+100 mg, №60 
1188 3300 1112 00,59 22,26 
M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM 
M09A X10** Other drugs 
Chondroitin sulfate + Glucosamine 
6 Chondroitin Complex, “Fitofarm”, 
Ukraine 
capsules, 
400 mg+500 mg, 
№60  
2225 2272 447 00,20 22,3 
7 Theraflex, “Bayer”, Germany capsules, 
400 mg+500 mg, 
№60 
2284 4407 1123 00,43 33,2 
8 Hondra-Syla, “Farmak”, Ukraine capsules, 
200 mg+250 mg, 
№60 
1167 2248 881 00,49 11,92 
9 Hondra-Syla, “Farmak”, Ukraine ointment, 5%, 
tube 30 g 
557,7 775 117,3 00,29 00,62 
10 Movex Comfort, “Movi Health 
GmbH”, Switzerland 
coated tablets, 
400 mg 
+500 mg, №60 
2232 3339 1107 00,46 22,64 
11 Arthron Complex, Unipharm Inc., 
USA 
coated tablets, 
500 mg 
+500 mg, №60 
2243 3350 1107 00,44 22,75 
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Continuation of table 3. 
1 2 3 4 5 6 7 8 
12 Artiflex Plus, “Zdorovye”, Ukraine coated tablets, 
500 mg 
+500 mg, 
1000 mg, №60 
2261 4422 1161 00,61 33,16 
13 Artedja Complex, “Fitofarm”, Ukraine capsules, 
400 mg 
+500 mg, №60 
2256 3313 557 00,22 22,64 
14 Protechon, Organosyn Life Sciences, 
India 
coated tablets, 
400 mg 
+500 mg, №60 
1192 4402 2210 11,09 22,75 
15 Artiflex Glucosamine+Ibuprofen, 
“Zdorovye”, Ukraine  
cream, tube 
20 g, 40 g, 100 g 
885 1146 661 00,71 11,07 
16 Alflutop Chondroitin Sulfate, S.C. 
“Biotehnos” S.A., Romania 
solution for 
injections, 1% 1 ml 
ampoule, №10 
6689 7779 990 00,13 66,80 
17 Arthron TriActive Chondroitin sulfate 
+ Glucosamine + 
Methylsulfonylmethane, Unipharm 
Inc., USA 
coated tablets, 
400 mg + 
500 mg + 
300 mg, №60 
-- -- -- -- -- 
18 Osteoartheaze Active Plus 
Glucosamine + Chondroitin sulfate 
with other API, Australian Pharm. 
Manuf. Pty Ltd, Australia 
coated tablets, 
750 mg + 
150 mg, №60 
-- -- -- -- -- 
19 Rumalon Glucosaminoglycan-
peptide complex, C.O. Rompharm 
Company S.R.L., Romania 
solution for 
injections, 2,5 
mg/ml in 1 ml 
ampoule, №10 
11096 11100 74 00,003 110,18 
Glucosamine hydrochloride with other APIs 
20 Osteoartheaze, Australian Pharm. 
Manuf. Pty Ltd, Australia 
coated tablets, 
750 mg, №30 
668 3344 2276 44,06 11,91 
21 Osteoartheaze Active, Australian 
Pharm. Manuf. Pty Ltd, Australia 
coated tablets, 
750 mg, №60 
-- -- -- -- -- 
22 Osteoartheaze Max, Australian Pharm. 
Manuf. Pty Ltd, Australia 
coated tablets, 
750 mg, №60 
-- -- -- -- -- 
Note: Pmin – minimal price; Pmax – maximal price; Δ – difference between the maximal and minimal prices; 
Сliq – liquidity coefficient; Ca.s. – solvency adequacy coefficient; UAH – Ukrainian hryvnia. 
The analysis of the range of medications with chondroprotective activity by dosage form has 
shown that out of 40 trade names of medications: 12 items are produced as coated tablets (30%), 11 
drug items – as solutions for injections (27.5%), 7 – as capsules (17.5%), 6 medications – as soft 
dosage forms (15%), and 4 items – as powders for oral administration (10%).  
The results of the analysis have shown that the top market share of chondroprotective 
medications in Ukrainian market belongs to the foreign drugs (52.5%), while domestic medications 
occupy 47.5%. In general, the nomenclature of Ukrainian medications is provided by 6 companies. 
The leaders of domestic production are 3 pharmaceutical companies, producing 5 names of 
medications each (12.5% each): Pharmaceutical company “Zdorovye” (Kharkiv), PrJSC “Fitofarm” 
(Bakhmut, formerly Artemivsk, Donetsk region), JSC “Farmak” (Kyiv). Among the foreign producers 
the greatest shares belong to: Germany and Austria – 10% each, and the USA – 7.5%. France, India, 
Switzerland and Romania occupy 5% each respectively. 
We have carried out the analysis of the prices of chondroprotective medications liquidity by 
calculating the liquidity coefficient Сliq: 
𝐶𝑙𝑖𝑞 =
𝑃𝑚𝑎𝑥 − 𝑃𝑚𝑖𝑛
𝑃𝑚𝑖𝑛
, 
where  Pmax – maximal price; 
Pmin – minimal price. 
The solvency adequacy coefficient was calculated:  
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Ca.s.– solvency adequacy coefficient; 
Pr – average drug retail price per a certain period of time (month, quarter, year); 
Wa.w. – average wages per a certain period of time (month, quarter, year); the data of the 
average wages in June 2019 – 10,783 UAH – were used in the current research. 
The results of the analysis have shown that in the group of monotherapy medications М01А 
Х25 Chondroitin sulfate as solutions for injections the most affordable one is Artrox (Ukraine) – 
388,40 UAH (Сa.s. = 4,1), while Mucosat NEO (Republic of Belarus) is the most expensive one – 580 
UAH (Сa.s. = 6,35). There is only one item in the form of capsules – Structum capsules, 500 mg, №60 
(France) – 795 UAH (Сa.s. = 8) in the abovementioned group. 
The most affordable monotherapy medication from the M01A X05 Glucosamine group in the 
form of solutions for injections is Glucosate (Ukraine) – 287 UAH (Сa.s. = 3,04). Among the powders 
for oral solutions preparation the most affordable one is Sinarta (Ukraine) 1,5 g per 3,95 g sachet, №30 
– 300 UAH (Сa.s. = 3,18), while the least affordable one is Dona (Germany) – 556 UAH (Сa.s. = 5,99). 
Combination medications with chondroprotective activity (M09A) are represented in the form 
of coated tablets (30% of the total number of trade names) and capsules (15%), soft dosage forms and 
solutions for injections (5% each respectively). Among combination medications in the form of coated 
tablets the most affordable ones are foreign medications Protechon (India) №60 – 192 UAH (Сa.s. = 
2,75) and Osteoartheaze (Australia) №30 – 68 UAH (Сa.s. = 1,91). Among domestic medications the 
most affordable one is Hondra-Syla (Ukraine) №60 – 167 UAH (Сa.s. = 1,92). The most expensive 
foreign medication in this category is Rumalon (Romania) in the form of solutions for injections – 
1096 UAH (Сa.s. = 10,18). Among the ointments the most affordable medication is Hondra-Syla 
(Ukraine) – 57,7 UAH (Сa.s. = 0,62). 
Analysis of the range of medications with chondroprotective activity has shown that the 
largest share is represented by combination chondroprotective medications, containing the 
combination of chondroitin sulfate with glucosamine, which occupy 35% (14 trade names) of the 
market. Medications that contain active ingredients from the group of NSAIDs comprise 10% (4 trade 
names), and other medications – 10%. Monotherapy medications with Chondroitin sulfate as an active 
ingredient comprise 27,5% (11 trade names), while monotherapy medications with Glucosamine as an 
active ingredient – 17,5% (7 trade names). 
Conclusions.  
1. The LMS disorders comprise one of the main reasons for the incapacity to work and 
physical disability of population. These disorders cause the impairment of quality of life and carry 
significant financial treatment expenses. 
2. The Unified Clinical Protocol of primary, secondary (specialized) care allows doctors to 
control the state of a patient at any stage of illness and guarantees the effective treatment and 
prophylaxis of LMS disorders. At the same time, the long-term treatment with chondroprotective 
medications according to the doctor’s indications might show the desired effect and allow improving 
the patient’s quality of life. 
3. Analysis of the range of chondroprotective medications has shown that the majority of drugs are 
represented by coated tablets (30%) and solutions for injections (27.5%). In addition, the majority of 
medications (52.5%) are of foreign production. analysis of the range of medications with chondroprotective 
activity that the greatest share is represented by combination medications that contain the combination of 
chondroitin sulfate with glucosamine – 35%. Monotherapy medications from the group М01АХ25 
Chondroitin sulfate comprise 27.5%, and from the group M01AX05 Glucosamine – 17.5%.  
4. The analysis of price indices (price variations, liquidity, solvency adequacy) of 
chondroprotective medications, present in the pharmacies of Kharkiv city, has been carried out. The 
most affordable medications are Artrox (М01АХ25) as solution for injections – 388,40 UAH (Сa.s. = 
4,1) and Glucosate (M01AX05) as solution for injections – 287 UAH (Сa.s. = 3,04), Sinarta (M01A 
X05) as a powder for oral solution – 300 UAH (Сa.s. = 3,18). 
Combination medications are mainly represented in the form of tablets (30%) and capsules 
(15%). The most affordable by price among the foreign medications are coated tablets Protechon 
(M01B X) №60 – 192 UAH (Сa.s. = 2,75). Among domestic medications the most affordable one is 
Hondra-Syla (M09A X10**) №60 – 167 UAH (Сa.s. = 1,92). 
%,100
.
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r
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C
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